@article{98657f7d31a94aa8a97a8c3f73efc639,
title = "Magnetic Resonance-Guided Drug Delivery",
keywords = "Cancer, Drug delivery, High-intensity focused ultrasound, Imaging guidance, MR imaging, Nanomedicine, Thermosensitive liposome, Tumor targeting",
author = "Mikhail, {Andrew S.} and Ari Partanen and Pavel Yarmolenko and Venkatesan, {Aradhana M.} and Wood, {Bradford J.}",
note = "Funding Information: This work was supported by the Center for Interventional Oncology in the Intramural Research Program of the National Institutes of Health (NIH). NIH and Celsion Corp. have a Cooperative Research and Development Agreement (CRADA). NIH and Philips Healthcare have a CRADA supported by NIH Grant # Z1A CL040015-06. Dr A. Partanen is a paid employee of Philips Healthcare . The content of this article does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. ",
year = "2015",
month = nov,
doi = "10.1016/j.mric.2015.05.012",
language = "English (US)",
volume = "23",
pages = "643--655",
journal = "Magnetic resonance imaging clinics of North America",
issn = "1064-9689",
publisher = "W.B. Saunders Ltd",
number = "4",
}